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Background: Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus of the genus Nairovirus family
Bunyaviridae, which are enveloped viruses containing tripartite, negative polarity, single-stranded RNA. CCHF is
characterized by high case mortality, occurring in Asia, Africa, the Middle East and Europe. Currently, there are no
specific treatments or licensed vaccines available for CCHFV. Recently, two research groups have found adult mice
with defective interferon responses allowed to lethal CCHFV infection. These mouse models could provide
invaluable information for further studies. Efforts to develop a vaccine against CCHFV are being made. To determine
the efficacy of vaccine candidates it is important to conduct serological studies that can accurately measure levels
of protective antibodies. In the present study, a pseudo-plaque reduction neutralization test (PPRNT) based on
enzyme-catalyzed color development of infected cells probed with anti-CCHFV antibodies was used to measure
neutralization antibody of CCHFV.
Methods: Sixty-nine human serum samples (20 acute and 49 convalescent) were tested. The presence of CCHFV
antibodies was determined and confirmed by a commercial ELISA kit. CCHFV RNA was determined by RT-PCR. All
the samples were analyzed by PPRNT and fluorescent focus reduction neutralization test (FFRNT) to measure of
CCHFV-neutralizing antibodies.
Results: Pseudo-plaque reduction neutralization test showed a high sensitivity (98%), specificity (100%) and
agreement (96,6%) in qualitative comparison with those of the FFRNT. There was a high correlation between the
titers obtained in PPRNT and FFRNT (R2 = 0.92). The inter- and intra-assay variation of PPRNT revealed good
reproducibility and positive cut-off of PPRNT was defined as 1:4 by the geometric mean titers for the individual
samples distributed.
Conclusion: The pseudo-plaque reduction neutralization test described in this study is a fast, reproducible and
sensitive method for the measurement of CCHF neutralizing antibodies. This novel assay could serve as useful tools
for CCHF research in epidemiology, vaccine development and other studies of immunity. It also provides an
alternative to PRNT when viruses with no or poor CPE in cell culture.
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Crimean-Congo hemorrhagic fever virus (CCHFV) is a
tick-borne virus of the genus Nairovirus family Bunya-
viridae, which are enveloped viruses containing tripar-
tite, negative polarity, single-stranded RNA [1,2].
Crimean-Congo hemorrhagic fever, a severe viral human
disease, is characterized by sudden onset of fever, head-
ache, abdominal pain, nausea, vomiting, extensive
ecchymoses, bleeding, and hepatic dysfunction with
fatality rates up to 30% [3,4]. The virus is transmitted to
humans by the bite of infected ticks, by squashed ticks,
or by exposure to the tissue or blood of infected live-
stock [5,6]. Crimean-Congo hemorrhagic fever virus can
spread from person to person through contact with the
tissue or blood of CCHF patients. It is one of the rare
hemorrhagic fever viruses capable of inducing nosoco-
mial outbreaks which may result in a more severe illness
with a higher mortality rate [7-10].
Crimean-Congo hemorrhagic fever is diagnosed
genetically by detection of viral RNA in acute-phase
blood sample or serum [3,4,9-12]. Serological diagnosis
relies on detection of anti-CCHF specific IgM and IgG
in enzyme-linked immunosorbent (ELISA) and immuno-
fluorescence assays (IFA) from paired acute and
convalescent specimens [13-17]. Ideally, the confir-
mation of CCHF infection should be made by
neutralization assay which is one of the most specific
serological methods. Virus neutralization tests are
usually based on the cytopathic effect (CPE) or the
plaque-reduction neutralization test (PRNT) [18,19].
The CPE assay relies on the visual examination of the
damage in magnified infected target cells. It is subjected
to observer variation and it is difficult to make a quanti-
tative determination of neutralizing activity based on the
CPE. The PRNT has limitations for screening the large
numbers of serum samples needed for epidemiological
investigations. Neither CPE assay nor PRNT can be used
to measure neutralization antibodies if the virus pro-
duces little or no CPE.
A pseudo-plaque reduction neutralization test (PPRNT)
based on enzyme-catalyzed color development of infected
cells probed with anti-CCHFV antibodies was used to
measure neutralization antibody of CCHFV. The results
obtained by PPRNT were compared with those of a fluor-
escence focus reduction neutralization test (FFRNT).
Results
CCHFV pseudo-plaque reduction neutralization assay
Crimean-Congo hemorrhagic fever Turkey-Kelkit06
strain does not produce plaques. We have been able to
titrate the virus by the recently developed pseudo-plaque
assay (PPA) described by Mitchell et al. [20] with some
modifications. A pseudo-plaque reduction neutralization
test was applied to CCHFV-neutralizing antibodydetection in a 96-well microplate scale. Crimean-Congo
hemorrhagic fever from challenged serial dilutions of
human serum was grown on a Vero E6 cell line. After
3 days of infection and cell permeabilization, detection
of the CCHFV pseudo-plaque was accomplished using
polyclonal mouse anti-CCHFV serum primary antibody
and β-gal-coupled anti-mouse IgG-antibody. The reac-
tion was apparent with X-gal substrate. The viral
pseudo-plaques stained medium blue to dark purple
(Figure 1a). We also conducted a fluorescent focus
reduction neutralization test (FFRNT) to measure of
CCHFV-neutralizing antibodies to compare with PPRNT
(Figure 1b).
Reproducibility of pseudo-plaque reduction neutralization
assay
In order to express reproducibility of the PPRNT results,
we reported two measures of the Coefficient of Variabi-
lity (CV); the Inter-Assay CV and the Intra-Assay CV.
The CV is a number defined as the standart deviation of
a distribution divided by its mean. In this study, the
inter-assay CV expression of plate-to-plate consistency
is calculated from the mean values for the high (n=2),
medium (n=2) and low (n=2) controls on each plate.
The six serum samples with known neutralization titers
were tested by PPRNT and were run in duplicate in
consecutive experiments to assess inter-assay variability
(Table 1). To evaluate the intra-assay CV which is the
average coefficient of variation between duplicates, sixty-
nine human serum samples (20 acute and 49 convales-
cent) were tested five times by PPRNT (Table 1). The
inter-assay coefficient of variation for samples ranged
from 2.48% to 9.82% (mean 5.71%), whereas the intra-
assay ranged from 4.63% to 10.81% (mean 7.44%)
Comparison of PPRNT and FFRNT
To validate to PPRNT for measuring CCHFV-neutralizing
antibodies, 69 human sera (20 acute and 49 convalescent)
with known FFRNT titers were tested by PPRNT. The
results of FFRNT were regarded as the gold standard and
as shown in Table 2, the sensitivity and specificity of
PPRNT were 98 and 100%, respectively. The agreement
and kapa statistics of PPRNT and FFRNT were 96.6 and
0.96%, respectively. A single sample of the 69 assessed was
FFRNT positive, although it was negative by PPRNT
(Table 2). From the distribution of geometric mean titers
for the individual samples, a positive cut-off for FFRNT
and PPRNT was defined as 1:4. There was a strong correl-
ation between the titers obtained in PPRNT and FFRNT
(R2 = 0.92; Figure 2).
Discussion
Crimean-Congo hemorrhagic fever virus is reported in
many countries of Africa, Asia, the Middle East, and
Figure 1 Vero E6 cells infected with CCHFV Turkey-Kelkit06 under light microscopy (×40). (a) and fluorescent microscopy (x40) (b)
showing the presence (on the right) and absence (on the left) of pseudo-plaque forming units (a) and fluorescent focus-forming units (b). Cells
were stained 72 h post-infection (PI).
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expanded in recent decades. An increasing number of
epidemics and sporadic cases have been reported in
Kosovo, Bulgaria, Albania, Greece, the Russian Fede-
ration, Tajikistan, Kazakhstan, Georgia, Iran, Pakistan,
Afghanistan, Mauritania, Senegal, Kenya, and India
[9,10]. While serological evidence of CCHF has been
found among humans since the 1970s, the first clinical
CCHF infection was recognized in 2002. Currently, an
exceptional outbreak of CCHF is occurring in Turkey
with more than 7,000 cases reported creating a serious
threat to public health [21-24].
Currently there are no specific treatments or licensed
vaccines available for CCHFV. There have been few
attempts to develop a vaccine because of the sporadicTable 1 Intra and inter-assay variations in PPRNT
Virus Input Intra-assay variation
Ratio between duplicate test in same serum
<4 4-7 7-10
n (%) n (%) n (%)
50 PPFU/well 20 (28.98) 33 (47.85) 16 (23.18)
*Neutralizing anti-CCHF antibodies titers were directly assigned to the highest dilut
**GMT; geometric mean titer, CV; coefficient of variance = (S.D./mean) × 100%, whiand limited numbers of cases, the lack of a suitable ani-
mal model to evaluate efficacy of vaccine candidates,
and the high level biocontainment facilities required for
working with the virus [25-27]. Recently, two research
groups have found adult mice with defective interferon
responses allowed to lethal CCHFV infection [28,29].
These mouse models could provide invaluable informa-
tion for further studies. Efforts to develop a vaccine
against CCHFV are being made.
To determine the efficacy of vaccine candidates it is
important to conduct serological studies that can accu-
rately measure levels of protective antibodies. Reports
on measuring neutralizing antibodies against CCHFV
are limited, and the neutralizing antibody response is
weak and difficult to demonstrate in CCHF infectionsInter-assay variation
*Six sera with known FFRNT
Total 32 (n=2) 128 (n=2) 512 (n=2)
n **GMT(CV) GMT(CV) GMT(CV)
69 36.76 (4.63) 111.4 (7.70) 445.70 (10.81)
27.86 (9.19) 147.0 (4.79) 588.10 (7.53)
ion with > 50% reduction.
ch was calculated with logarithmic transformation.
Table 2 Qualitative comparison between PPRNT and FFRNT
FFRNT Sensitivity (%) Specificity (%) Agreement (%) Kappa
> 4 < 4 *(95% CI) (95% CI) (95% CI)
PPRNT
> 4 49 1 98.0 100 96.6 0.96
< 4 0 20
*Fold differences were calculated based on the within and between assay standard deviation of log10 titres within which results from testing a sample twice
should fall 95% of the time.
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CCHF are most commonly measured using plaque
reduction neutralization assay, which requires a mono-
layer of cells susceptible to the virus infection. However,
the use of cell lines for CCHFV may produce little or no
CPE, since the virus tends to develop a noncytopathic
persistent infection, depending on the strain. An alterna-
tive method of measuring CCHF-neutralizing antibody
response is fluorescent focus reduction neutralization
assay (FFRNT). The two published reports on the detec-
tion of CCHF-neutralizing antibody with FFRNT are not
recent [30,31]. In the present study, we developed
PPRNT, based on colorimetric immunoassay used for
infectious particle assay and clonal isolation of adeno-
associated virus [20]. Fluorescent focus reduction
neutralization assay was adapted for the measurement of
neutralizing antibody responses against CCHF, and the
results of FFRNT were regarded as the gold standard.
Parameters such as sensitivity, specificity, and repro-
ducibility are important to evaluate when developing
new or modified laboratory tests. In this study, the inter-
and intra-assay variation of PPRNT revealed good repro-
ducibility (Table 1). The PPRNT showed high sensitivity
(98%), specificity (100%), and agreement (96.6%) in
qualitative comparison with FFRNT (Table 2). The titersFigure 2 Correlation of the mean neutralizing titers of 69
serum samples determined by FFRNT and PPRNT. Based on the
distribution, a positive cut-off value of 1:4 was defined for PPRNT
and FFRNT. The solid line indicates complete correlation.obtained by PPRNT and FFRNT were highly correlated
(R2 = 0.92; Figure 2). In addition, we were able to define
for both assays a positive cut-off (1:4) based on the geo-
metric mean titers for the individual samples distributed.
There was no significant difference between PPRNT and
FFRNT with respect to determining CCHF-neutralizing
antibody response. This is not surprising since both
methods are based on the same fundamental principles
and differ only in the surface area of the tissue culture
plates and in the final visualization steps. However, a
unique advantage of PPRNT is that the pseudo-plaques
can be counted using the naked eye or by light micros-
copy. Moreover, the plates containing pseudo-plaques
can be stored for an extended period of time.
Unlike the standard plaque reduction neutralization
test, PPRNT does not require cell destruction or damage
by the virus infection. It allows the use of virus strains
that do not form plaques, such as CCHFV Turkey-
Kelkit06, for the measurement of neutralizing antibodies.
Therefore, results can be more rapidly obtained by
PPRNT (3 days after infection) than with PRNT (usually
5 to 7 days after infection). Another potential advantage
of the PPRNT compared to standard PRNT is that
PPRNT is performed in 96-well plates, enabling investi-
gation of a large number of samples.
In conclusion, the pseudo-plaque neutralization assay
described here is a rapid, reproducible, and sensitive
method for the measurement of CCHF neutralizing anti-
bodies. This novel, high-throughput assay could serve as
a useful tool for CCHF research in epidemiology, vaccine
development, and other studies of immunity. It also pro-
vides an alternative to PRNT when viruses with no or
poor CPE in cell culture.
Methods
Cells, virus, and antibodies
Vero E6 cells (African green monkey kidney) obtained
from ATCC (CRL 1586) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS), 100 mM
Lglutamine, 50 U ml-1 penicillin, and 50 μg ml-1 strepto-
mycin (Sigma-Aldrich, Germany).
The CCHFV Turkey-Kelkit06 strain was isolated from
a patient in Turkey [33]. CCHFV Turkey-Kelkit06 was
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2-3 day old suckling mice. The CCHFV stocks were pre-
pared on Vero E6 cells by infection of T175 cell culture
flasks with a 1:100 dilution. Supernatants were collected
on days 4 and 5 post-infection (PI), cleared of cell debris
by centrifugation at 500 g for 20 min at 4°C, and
aliquots were stored at -80°C. The titer of the viral stock
was quantified at 4.3×105 ml-1 using a pseudo-plaque
assay [34]. All handling of virus was conducted in a bio-
safety level 3 laboratory (BSL-3).
To produce the primary antibodies, after cultivation of
CCHFV infected Vero E6 cells the viral particles were
obtained by using sucrose gradient ultracentrifugation
and the gradients which intensely contain viral specific
particles were collected to make purification of the virus.
Inactivation of the virus by formaldehyde was followed
by dialysis (MWCO 20 kDa, Millipore, Bedford, MA)
with phosphate-buffered saline. The protein concentra-
tion of the fractions were determined a colorimetric
assay (Bicinchoninic acid protein assay kit, Sigma–
Aldrich). New Zealand white rabbits received 100 micro-
gram of the viral antigen adjuvanted with ALUM on day
1, 21, 42. Balb-C mice received 50 microgram of the
viral antigen adjuvanted with ALUM on day 1, 21, 42.
Blood samples were taken every week and tested by
ELISA to determine whether they`re positive anti-
CCHFV IgG. After purification of the IgGs from the
rabbits and mice they were used as primary antibodies
in this method.
The entire protocol and the animal experiments were
approved by the Ethics Committee of Firat University.
Serum samples
Sixty-nine human serum samples (20 acute and 49
convalescent) were tested. The presence of CCHFV
RNA was confirmed by RT-PCR for the acut samples as
described elsewhere [35]. The presence of anti-CCHFV
IgG for the 49 convalescent was confirmed by a com-
mercial ELISA kit (vectorbestWRussia). Written informed
consent for participation in the study was obtained from
participants. All sera were heated at 56°C for 30 min to
eliminate serum complement.
Pseudo-plaque reduction neutralization test (PPRNT)
The CCHFV pseudo-plaque reduction neutralization
assay was performed in 96-well microtiter plates. Vero
E6 cells were grown to confluence with DMEM contain-
ing 10% FBS in 96-well micro titer plate (Corning, USA)
at 37°C, 5% CO2 for 18-24 h. Human serum samples
diluted 1:4 in Eagle’s MEM (EMEM) were heat-
inactivated at 56°C for 30 min. Two-fold serial dilutions
from 1:4 to 1:4.096 were prepared in virus diluent
(EMEM with L-glutamine containing 1% FBS, 2%
HEPES (1 M), and 1% penicillin, streptomycin 100×).Serial dilutions of the test specimens were challenged
with approximately 50 pseudo-plaque forming units
(ppfu) incubated overnight at 4°C. Two hundred microli-
ters of the serum–virus mixtures were adsorbed to
confluent cell monolayers (in duplicate) and incubated
for an additional hour at 37°C. The supernantant was
removed, and the cell monolayer was overlaid with the
virus medium (DMEM with L-glutamine containing 2%
FBS, 2% HEPES (1 M), and 1% penicillin, streptomycin
100×) supplemented with 1% carboxy methyl cellulose
(Sigma-Aldrich, Germany) and incubated at 37°C, 5%
CO2 for 3 days. The cells were fixed with a solution of
10% buffered neutral formaldehyde in PBS. After 20 min
the formaldehyde solution was aspirated, the cells were
washed twice with TBST (100 mM Tris-HCl pH 8.0,
1.5 M NaCl, 1% Tween 20), permeated with 0.1% Triton
X 100 in PBS for 20 min and blocked with 5% skim milk
in PBS. Polyclonal mouse anti-CCHFV serum (1:1500)
was added to each well in TBST and incubated for 1 h at
room temperature with gentle rocking. Following three
10 min washes in TBST, goat anti-mouse β-gal conjugate
diluted 1:1500 in TBST (Southern Biotech, USA) was
added to each well and incubated 1 h at room
temperature with gentle rocking. The cells were washed
five times with TBST, and the substrates nitro blue tetra-
zolium (NBT) and X-gal (5-bromo-4-choloro-3-indolyl-
beta-D-galactopyranoside) were added to each well and
incubated at 37°C. Microplates were checked microsco-
pically every 10 min. Neutralizing anti-CCHF antibody
titers were directly assigned to the highest dilution with
> 50% reduction.
Fluorescent focus reduction neutralization test (FFRNT)
Vero E6 cells at density of 3×105 ml-1 were seeded into
Lab Tek II 8-well chamber slides (Sigma-Aldrich,
Germany) at 37°C and 5% CO2 to achieve 80-90% con-
fluence the following day. Sera, including positive and
negative controls, were diluted 1:4 in EMEM inactivated
at 56°C for 30 min and serially diluted two-fold in
EMEM in 96-well tissue culture microplates. The plates
were incubated at 4°C overnight with an equal volume
CCHFV Turkey-Kelkit06 to provide approximately 50
ppfu per 100 μl. Two hundred microliters of the serum–
virus mixtures were added in duplicate to cell mono-
layers and allowed to adsorb for 1 h at 37°C. Inoculums
were aspirated, and slides were overlaid with 1% carboxy
methyl cellulose (Sigma-Aldrich,Germany) and incu-
bated at 37°C and 5% CO2 for 3 days. After fixation with
10% buffered neutral formaldehyde, the cells were per-
meated with 0.1% Triton X 100 in PBS for 20 min and
blocked with 5% skim milk in PBS. Slides were incu-
bated with rabbit anti-CCHFV polyclonal antisera
(1:1000) for 1 h in TBST at 37°C in a humid chamber.
Following three 10 min washes in TBST, antibody-
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goat anti-rabbit IgG conjugated with fluorescein isothio-
cyanate (FITCH) (Southern Biotech, USA) and diluted
1:1000 in TBST. After extensive washing, the cells were
mounted in anti-fading medium (Sigma-Aldrich,-
Germany) and analyzed by immunofluorescence micros-
copy (Olympus BX50, Japan). Neutralizing anti-CCHF
antibodies titers were directly assigned to the highest
dilution with > 50% reduction.
Statistical analysis
Statistical analysis was carried out using Graphpad Prism
5. The 95% confidence interval (95% CI) of sensitivity
and specificity were calculated. The intra-assay and
inter-assay variations of the neutralization test (NT)
results were determined and the result was given as a
coefficient of variation (CV) and geometric mean titer
(GM). Agreement and Kappa values were calculated
using SPSS 17.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
NC and EB carried out the study. MDY, ST, and YB participated in the
immunoassays. MA, AK and ME participated in the design of the study and
performed the statistical analysis. AO conceived of the study, and
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was financially supported and approved by the Scientific and
Technological Research Council of Turkey (TUBITAK), project number
108G126.
Author details
1Department of Virology, College of Veterinary Medicine, Firat University,
Elazig, Turkey. 2Refik Saydam National Public Health Agency, Ankara, Turkey.
3Department of Parasitology, College of Veterinary Medicine, Firat University,
Elazig, Turkey. 4Department of Infectious Diseases and Clinical Microbiology,
Medical Faculty, Karadeniz Technical University, Trabzon, Turkey. 5Department
of Microbiology, School of Medicine, Erciyes University, Kayseri, Turkey.
Received: 10 May 2012 Accepted: 24 December 2012
Published: 3 January 2013
References
1. Schmaljohn CS, Nichol ST: Bunyaviridae: the viruses and their replication.
In Fields virology, Volume 2. Fifth editionth edition. Edited by Knipe DM
HPM, Griffin DE. Philadelphia: Lippincott Williams; 2007:1741–1789.
2. Elliott RM, Schmaljohn CS, Collett MS: Bunyaviridae genome structure and
gene expression. Curr Top Microbiol Immunol 1991, 169:91–141.
3. Whitehouse CA: Crimean-Congo hemorrhagic fever. Antiviral Res 2004,
64:145–160.
4. Ergonul O: Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006,
6:203–214.
5. Hoogstraal H: The epidemiology of tick-borne Crimean-Congo
hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol 1979,
15:307–417.
6. Shepherd AJ, Swanepoel R, Cornel AJ, Mathee O: Experimental studies on
the replication and transmission of Crimean- Congo hemorrhagic fever
virus in some African tick species. Am J Trop Med Hyg 1989, 3:326–331.
7. Mardani M, Keshtkar-Jahromi M, Ataie B, Adibi P: Crimean-Congo
hemorrhagic fever virus as a nosocomial pathogen in Iran. Am J Trop
Med Hyg 2009, 4:675–678.8. Aradaib IE, Erickson BR, Mustafa ME, Khristova ML, Saeed NS, Elageb RM,
Nichol ST: Nosocomial outbreak of crimean-congo hemorrhagic fever.
Sudan. Emerging Infect Dis 2010, 16:837–839.
9. Ergonul O: Crimean-Congo hemorrhagic fever virus: new outbreaks, new
discoveries. Curr Opin Virol 2012, 2:215–220.
10. Leblebicioglu H: Crimean-Congo haemorrhagic fever in Eurasia. Int J
Antimicrob Agents 2010, 1:S43–46.
11. Burt FJ, Leman PA, Smith JF, Swanepoel R: The use of a reverse
transcription-polymerase chain reaction for the detection of viral nucleic
acid in the diagnosis of Crimean-Congo haemorrhagic fever. J Virol Meth
1998, 70:129–137.
12. Ozdarendeli A, Aydin K, Tonbak S, Aktas M, Altay K, Koksal I, Bolat Y, Dumanli
N, Kalkan A: Genetic analysis of the M RNA segment of Crimean-Congo
hemorrhagic fever virus strains in Turkey. Arch Virol 2008, 153:37–44.
13. Donets MA, Rezapkin GV, Ivanov AP, Tkachenko EA: Immunosorbent assays
for diagnosis of Crimean-Congo hemorrhagic fever (CCHF). AmJTrop Med
Hyg 1982, 31:156–162.
14. Burt FJ, Leman PA, Abbott JC, Swanepoel R: Serodiagnosis of Crimean-
Congo haemorrhagic fever. Epidemiol Infect 1994, 113:551–562.
15. Dowall SD, Richards KS, Graham VA, Chamberlain J, Hewson R:
Development of an indirect ELISA method for the parallel measurement
of IgG and IgM antibodies against Crimean-Congo haemorrhagic fever
(CCHF) virus using recombinant nucleoprotein as antigen. J Virol Methods
2012, 2:335–341.
16. Saijo M, Qing T, Niikura M, Maeda A, Ikegami T, Sakai K, Prehaud C, Kurane I,
Morikawa S: Immunofluorescence technique using HeLa cells expressing
recombinant nucleoprotein for detection of immunoglobulin G
antibodies to Crimean-Congo hemorrhagic fever virus. J ClinMicrobiol
2002, 40:372–375.
17. Garcia S, Chinikar S, Coudrier D, Billecocq A, Hooshmand B, Crance JM,
Garin D, Bouloy M: Evaluation of a Crimean-Congo hemorrhagic fever
virus recombinant antigen expressed by Semliki Forest suicide virus for
IgM and IgG antibody detection in human and animal sera collected in
Iran. J Clin Virol 2006, 35:154–159.
18. Reed LJ, Muench H: A simple method of estimating fifty percent
endpoints. Am J Hygiene 1938, 27:493–497.
19. Dulbecco R, Vogt M: Plaque formation and isolation of pure lines with
poliomyelitis viruses. J Exp Med 1954, 99:167–182.
20. Mitchell DAJ, Lerch TF, Hare JT, Chapman MS: A pseudo-plaque method
for infectious particle assay and clonal isolation of adeno-associated
virus. J Virol Meth 2010, 170:9–15.
21. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, Akdogan E,
Eren N, Koksal I, Ovali E: Crimean-Congo hemorrhagic fever in Turkey.
Emerg Infect Dis 2004, 10:1379–1384.
22. Maltezou HC, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F,
Kalvatchev N, Nichol S, Niedrig M, Platonov A, Thomson G, Leitmeyer K,
Zeller H: Crimean-Congo hemorrhagic fever in Europe: current situation
calls for preparedness. Euro Surveill 2010, 15:19504.
23. Ergunay K, Whitehouse CA, Ozkul A: Current status of human arboviral
diseases in Turkey. Vector Borne Zoonotic Dis 2011, 6:731–741.
24. Gargili A, Midilli K, Ergonul O, Ergin S, Alp HG, Vatansever Z, Iyisan S, Cerit C,
Yilmaz G, Altas K, Estrada-Peña A: Crimean-Congo hemorrhagic fever in
European part of Turkey: genetic analysis of the virus strains from ticks
and a seroepidemiological study in humans. Vector Borne Zoonotic Dis
2011, 6:747–752.
25. Christova I, Kovacheva O, Georgieva G, Ivanova S, Argirov D: Vaccine
against Congo-Crimean haemorhagic fever virus—Bulgarian input in
fighting the disease. Probl Infect Parasit Dis 2010, 37:7–8.
26. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C:
Immunogenicity of combination DNA vaccines for Rift Valley fever virus,
tick- borne encephalitis virus, Hantaan virus, and Crimean Congo
hemorrhagic fever virus. Vaccine 2006, 24:4657–4666.
27. Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S:
Crimean-Congo hemorrhagic fever: current and future prospects of
vaccines and therapies. Antiviral Res 2011, 2:85–92.
28. Bente DA, Alimonti JB, Shieh WJ, Camus G, Stroher U, Zaki S, Jones SM:
Pathogenesis and immune response of Crimean-Congo hemorrhagic fever
virus in a STAT-1 knockout mouse model. J Virol 2010, 84:11089–11100.
29. Bereczky S, Lindegren G, Karlberg H, Akerstrom S, Klingstrom J, Mirazimi A:
Crimean-Congo hemorrhagic fever virus infection is lethal for adult type
I interferon receptor-knockout mice. J Gen Virol 2010, 91:1473–1477.
Canakoglu et al. Virology Journal 2013, 10:6 Page 7 of 7
http://www.virologyj.com/content/10/1/630. Tignor GH, Smith AL, Casals J, Ezeokoli CD, Okoli J: Close relationship of
Crimean hemorrhagic fever-Congo (CHF-C) virus strains by neutralizing
antibody assays. AmJTrop Med Hyg 1980, 4:676–685.
31. Shepherd AJ, Swanepoel R, Leman PA: Antibody response in Crimean-
Congo hemorrhagic fever. Rev Infect Dis 1989, 4:S801–806.
32. Bertolotti-Ciarlet A, Smith J, Strecker K, Paragas J, Altamura LA, McFalls JM,
Frias-Stäheli N, García-Sastre A, Schmaljohn CS, Doms RW: Cellular
localization and antigenic characterization of crimean-congo
hemorrhagic fever virus glycoproteins. J Virol 2005, 10:6152–6161.
33. Ozdarendeli A, Canakoğlu N, Berber E, Aydin K, Tonbak S, Ertek M, Buzgan T,
Bolat Y, Aktaş M, Kalkan A: The Complete genome analysis of Crimean-
Congo hemorrhagic fever virus isolated in Turkey. Virus Res 2010,
147:288–293.
34. Berber E, Canakoğlu N, Yoruk MD, Tonbak S, Aktaş M, Ertek M, Bolat Y,
Kalkan A, Ozdarendeli A: Application of the pseudo-plaque assay for
detection and titration of Crimean-Congo hemorrhagic fever virus. J Virol
Methods 2013, 187:26–31.
35. Tonbak S, Aktas M, Altay K, Azkur AK, Aydin K, Kalkan A, Bolat Y, Dumanli N,
Ozdarendeli A: Crimean-Congo hemorrhagic fever virus: genetic analysis
and tick survey in Turkey. J Clin Microbiol 2006, 44:4420–4124.
doi:10.1186/1743-422X-10-6
Cite this article as: Canakoglu et al.: Pseudo-plaque reduction
neutralization test (PPRNT) for the measurement of neutralizing
antibodies to Crimean-Congo hemorrhagic fever virus. Virology Journal
2013 10:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
